Nurix Therapeutics
NRIX
123 hedge funds and large institutions have $377M invested in Nurix Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 14 closing their positions.
11,242% more call options, than puts
Call options by funds: $2.15M | Put options by funds: $19K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
3% more funds holding
Funds holding: 119 → 123 (+4)
0.65% less ownership
Funds ownership: 90.52% → 89.86% (-0.65%)
19% less capital invested
Capital invested by funds: $462M → $377M (-$85.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.62M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.62M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.39M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.62M |
| 5 |
BlackRock
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.97M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.77M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$4.75M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.84M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$2.62M |
NRIX Hedge Fund Activity: Q1 2023 in Review
123 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2023, worth a combined $377M — down 19% from $462M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NRIX positions and 14 closed out — a net gain of 4 holders — while 45 added to existing stakes and 37 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $7.62M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.97M.
- 123 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2023, up from 119 in Q4 2022.
- Funds reported $377M of Nurix Therapeutics stock for Q1 2023, down 19% quarter-over-quarter.
- 18 funds opened new Nurix Therapeutics positions in Q1 2023 and 14 closed out, a net change of +4 holders.
- The largest Nurix Therapeutics buyer in Q1 2023 was Deep Track Capital, an estimated $7.62M added.
- The largest Nurix Therapeutics seller in Q1 2023 was T. Rowe Price Associates, an estimated $6.97M sold.
Based on aggregated 13F filings for Q1 2023.